aminoglutethimide has been researched along with Neoplasm Metastasis in 104 studies
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inhibition of estrogen action at the target tissue level with the antiestrogen, tamoxifen, has proved highly successful in the treatment of hormone-responsive breast cancer." | 10.16 | Tamoxifen therapy of metastatic breast cancer. ( Manni, A, 1987) |
| "The efficacy of combined endocrine therapy with tamoxifen (TAM), aminoglutethimide (AG), and hydrocortisone (H) or tamoxifen and fluoxymesterone (FLU) was evaluated against treatment with tamoxifen alone in 311 patients above 65 years of age with a first recurrence of a metastatic breast cancer." | 9.09 | Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. ( Andersen, J; Andersson, M; Bastholt, L; Christensen, IJ; Dombernowsky, P; Kamby, C; Mouridsen, HT; Munkholm, P; Møller, KA; Rose, C, 2000) |
| "In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared." | 9.06 | Megestrol acetate versus aminoglutethimide for metastatic breast cancer. ( Gundersen, S; Klepp, R; Kvinnsland, S; Lund, E; Lundgren, S; Lønning, PE, 1989) |
| "One hundred and twenty patients with metastatic breast cancer, whose disease progressed on hormonal therapy with tamoxifen, were treated with aminoglutethimide." | 9.06 | Second line hormonal therapy with aminoglutethimide in metastatic breast cancer. ( Biran, S; Brufman, G, 1990) |
| "The therapeutic efficacy of combined endocrine therapy with tamoxifen, aminoglutethimide and hydrocortisone (T+AG+H) was evaluated against treatment with tamoxifen (T) alone in 210 patients above 65 years of age with metastatic breast cancer." | 9.06 | Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. ( Andersen, AP; Andersen, KW; Bastholt, L; Brincker, H; Dombernowsky, P; Kamby, C; Loft, H; Mouridsen, HT; Rose, C; Skovgaard-Poulsen, H, 1986) |
| "Aminoglutethimide, a drug known to block adrenal steroidogenesis and peripheral aromatization of androgens to estrogens, has been found effective in the treatment of breast cancer." | 9.05 | Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer. ( Ardizzoni, A; Conte, P; Lionetto, R; Pronzato, P; Rosso, R, 1985) |
| "Seventy-four post-menopausal women with metastatic breast cancer were treated with a combination hormonal regimen consisting of tamoxifen, aminoglutethimide danazol and medroxyprogesterone acetate (POND)." | 7.68 | Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. ( Ashley, SE; Coombes, RC; Ellin, CL; Hardy, JR; Judson, IR; Powles, TJ; Sinnett, HD, 1990) |
| "44 postmenopausal women with progressive soft tissue, osseous and/or pleuropulmonal metastases of breast cancer were treated with aminoglutethimide (Rodazol) and hydrocortisone." | 7.68 | [Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer]. ( Brockmann, B; Geschke, E; Schmidt, UM, 1991) |
| "This study was performed to determine the toxicity and effectiveness of megestrol acetate used with aminoglutethimide-hydrocortisone in the treatment of patients with metastatic breast cancer." | 7.67 | Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. ( Gale, KE; Hahn, RG; Horton, J; Keller, AM; Knuiman, M; Rosenbluth, RJ; Tormey, DC; Vogel, H, 1987) |
| "Seventy-nine postmenopausal patients received aminoglutethimide (AG; 750 mg daily) and hydrocortisone therapy for metastatic or locally recurrent breast cancer following the failure of other hormonal therapy." | 7.67 | Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity. ( Gilmore, OJ; Plowman, PN; Rowell, NP, 1987) |
| "Administration of orimeten (aminoglutethimide), for disseminated breast cancer in 38 postmenopausal females, in whom other treatment modalities had failed, proved effective in 39%." | 7.67 | [The use of aminoglutethimide (orimeten) in disseminated breast cancer]. ( Bassalyk, LS; Garin, AM; Lichinitser, MR; Nadezhdina, TM; Vyshinskaia, GV, 1987) |
| "Sixty patients suffering from metastatic breast cancer, whose disease progressed on chemotherapy and/or hormonal therapy with tamoxifen, were treated with aminoglutethimide." | 7.67 | Treatment of metastatic breast cancer with aminoglutethimide after progression on chemotherapy and/or hormonal therapy with tamoxifen. ( Biran, S; Brufman, G, 1985) |
| "One hundred twenty-eight women with advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG) (1000 mg orally, daily) and medroxyprogesterone acetate (MPA) (1500 mg orally, daily for six weeks and thereafter 500 mg orally, daily; omitting cortisone substitution)." | 7.67 | Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). ( Blossey, HC; Kleeberg, U; Nagel, GA; Wander, HE, 1986) |
| "45 women (postmenopausal or after former oophorectomy) with metastatic breast cancer resistant to tamoxifen as well as to chemo- and radiotherapy were treated with aminoglutethimide (750 mg or 1000 mg resp." | 7.67 | [Aminoglutethimide therapy in advanced breast cancer]. ( Kühböck, J; Ludwig, H; Pötzi, P; Zielinski, C, 1985) |
| "Eighteen premenopausal patients with progressive metastatic breast cancer were treated with aminoglutethimide (AG)/cortisone." | 7.67 | Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. ( Blossey, HC; Nagel, GA; Wander, HE, 1986) |
| "Thirty-eight metastatic breast cancer patients were treated with aminoglutethimide." | 7.66 | Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. ( Blumenschein, GR; Buzdar, AU; Legha, SS; Powell, KC, 1982) |
| "We describe sequential response to aminoglutethimide after eventual failure of treatment with tamoxifen in a patient with metastatic breast cancer." | 7.66 | Response to aminoglutethimide after tamoxifen therapy in advanced breast cancer. ( Allison, RW; Furnival, CM; Lee, JF; Roberts, SJ, 1982) |
| "Sixty-five patients with actively progressing advanced breast cancer were treated with aminoglutethimide, a drug which inhibits adrenal steroid synthesis and decreases peripheral conversion of androgens to oestrogens." | 7.66 | Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer. ( Jerums, G; Murray, RM; Pitt, P, 1981) |
| "Seventy-three women with metastatic breast cancer were treated with aminoglutethimide and dexamethasone." | 7.66 | Treatment of metastatic breast cancer with aminoglutethimide. ( Asbury, RF; Bakemeier, RF; Bennett, JM; Fölsch, E; McCune, CS; Savlov, E, 1981) |
| "Aminoglutethimide was applied for treatment of 10 patients (8 postmenopausal, 2 ovariectomized) with metastasizing breast cancer." | 7.66 | [Treatment of metastasizing breast cancer with aminoglutethimide]. ( Aiginger, P; Kübböck, J; Linkesch, W; Ludwig, H; Pötzi, P, 1982) |
| "Two hundred and thirteen unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone." | 7.66 | Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Harmer, CL; Harris, AL; McKinna, JA; Morgan, M; Parsons, CA; Powles, TJ; Smith, IE; White, H, 1983) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 6.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "Inhibition of estrogen action at the target tissue level with the antiestrogen, tamoxifen, has proved highly successful in the treatment of hormone-responsive breast cancer." | 6.16 | Tamoxifen therapy of metastatic breast cancer. ( Manni, A, 1987) |
| "As breast cancer is responsive to hormonal therapy, AG has been used in the treatment of metastatic breast cancer." | 5.28 | [The use of aminoglutethimide in the treatment of metastatic breast cancer]. ( Bellora, MG; Bergamino, T; Ciancio, A; Ferrero, A; Sismondi, P; Zola, P, 1991) |
| "A total of 79 patients with metastatic breast cancer entered the study, and their plasma and urine samples were analyzed by high-performance liquid chromatography (HPLC)." | 5.27 | Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ( Höffken, K; Miller, AA; Miller, BE; Schmidt, CG, 1987) |
| "Aminoglutethimide is an investigational agent of proven benefit in the treatment of metastatic breast carcinoma." | 5.26 | Pancytopenia induced by aminoglutethimide in the treatment of breast cancer. ( Hamilton, R; Harvey, HA; Lawrence, B; Lipton, A; Mercurio, T; Santen, RJ, 1978) |
| "The efficacy of combined endocrine therapy with tamoxifen (TAM), aminoglutethimide (AG), and hydrocortisone (H) or tamoxifen and fluoxymesterone (FLU) was evaluated against treatment with tamoxifen alone in 311 patients above 65 years of age with a first recurrence of a metastatic breast cancer." | 5.09 | Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. ( Andersen, J; Andersson, M; Bastholt, L; Christensen, IJ; Dombernowsky, P; Kamby, C; Mouridsen, HT; Munkholm, P; Møller, KA; Rose, C, 2000) |
| "In order to evaluate the effectiveness of second and third line hormone therapy for postmenopausal (spontaneous or surgical) women with metastatic tamoxifen-resistant breast cancer, 293 women aged 36 to 91 (mean 63." | 5.07 | [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]. ( Ayme, Y; Carton, M; Daban, A; Delozier, T; Fargeot, P; Ferri, L; Fumoleau, P; Garcia-Giralt, E; Gorins, A; Omodei Zorini, C, 1994) |
| "The therapeutic efficacy of combined endocrine therapy with tamoxifen, aminoglutethimide and hydrocortisone (T+AG+H) was evaluated against treatment with tamoxifen (T) alone in 210 patients above 65 years of age with metastatic breast cancer." | 5.06 | Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. ( Andersen, AP; Andersen, KW; Bastholt, L; Brincker, H; Dombernowsky, P; Kamby, C; Loft, H; Mouridsen, HT; Rose, C; Skovgaard-Poulsen, H, 1986) |
| "In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared." | 5.06 | Megestrol acetate versus aminoglutethimide for metastatic breast cancer. ( Gundersen, S; Klepp, R; Kvinnsland, S; Lund, E; Lundgren, S; Lønning, PE, 1989) |
| "One hundred and twenty patients with metastatic breast cancer, whose disease progressed on hormonal therapy with tamoxifen, were treated with aminoglutethimide." | 5.06 | Second line hormonal therapy with aminoglutethimide in metastatic breast cancer. ( Biran, S; Brufman, G, 1990) |
| "One hundred-twenty-seven advanced breast cancer patients who had been -for most of them- heavily pretreated with chemo- and/or hormone therapy received 500 mg aminoglutethimide and 30 mg hydrocortisone/day." | 5.06 | [Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast]. ( Bonneterre, J; Demaille, A; Pion, JM, 1987) |
| "Aminoglutethimide, a drug known to block adrenal steroidogenesis and peripheral aromatization of androgens to estrogens, has been found effective in the treatment of breast cancer." | 5.05 | Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer. ( Ardizzoni, A; Conte, P; Lionetto, R; Pronzato, P; Rosso, R, 1985) |
| "Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy." | 4.82 | A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. ( Rose, C, 2003) |
| "59 women with metastatic breast cancer in menopause were treated with 1 g/day aminoglutethimide and 3 mg/d dexamethasone." | 3.68 | [Experiences with Rodazol therapy in the treatment of postmenopausal patients with metastatic breast cancer]. ( Gürtler, R; Müller, U; Schmidt, UM; Stier, G; Tanneberger, S, 1990) |
| "Seventy-four post-menopausal women with metastatic breast cancer were treated with a combination hormonal regimen consisting of tamoxifen, aminoglutethimide danazol and medroxyprogesterone acetate (POND)." | 3.68 | Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. ( Ashley, SE; Coombes, RC; Ellin, CL; Hardy, JR; Judson, IR; Powles, TJ; Sinnett, HD, 1990) |
| "44 postmenopausal women with progressive soft tissue, osseous and/or pleuropulmonal metastases of breast cancer were treated with aminoglutethimide (Rodazol) and hydrocortisone." | 3.68 | [Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer]. ( Brockmann, B; Geschke, E; Schmidt, UM, 1991) |
| "Administration of orimeten (aminoglutethimide), for disseminated breast cancer in 38 postmenopausal females, in whom other treatment modalities had failed, proved effective in 39%." | 3.67 | [The use of aminoglutethimide (orimeten) in disseminated breast cancer]. ( Bassalyk, LS; Garin, AM; Lichinitser, MR; Nadezhdina, TM; Vyshinskaia, GV, 1987) |
| "Seventy-nine postmenopausal patients received aminoglutethimide (AG; 750 mg daily) and hydrocortisone therapy for metastatic or locally recurrent breast cancer following the failure of other hormonal therapy." | 3.67 | Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity. ( Gilmore, OJ; Plowman, PN; Rowell, NP, 1987) |
| "One hundred twenty-eight women with advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG) (1000 mg orally, daily) and medroxyprogesterone acetate (MPA) (1500 mg orally, daily for six weeks and thereafter 500 mg orally, daily; omitting cortisone substitution)." | 3.67 | Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). ( Blossey, HC; Kleeberg, U; Nagel, GA; Wander, HE, 1986) |
| "Eighteen premenopausal patients with progressive metastatic breast cancer were treated with aminoglutethimide (AG)/cortisone." | 3.67 | Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. ( Blossey, HC; Nagel, GA; Wander, HE, 1986) |
| "Sixty patients suffering from metastatic breast cancer, whose disease progressed on chemotherapy and/or hormonal therapy with tamoxifen, were treated with aminoglutethimide." | 3.67 | Treatment of metastatic breast cancer with aminoglutethimide after progression on chemotherapy and/or hormonal therapy with tamoxifen. ( Biran, S; Brufman, G, 1985) |
| "Postmenopausal patients with metastatic breast cancer were treated with aminoglutethimide (AG) and high-dose medroxyprogesterone acetate (MPA)." | 3.67 | Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol. ( Blijham, GH; Mellink, WA; Meulenberg, PM; Van Deijk, WA, 1985) |
| "Marked leukopenia and/or thrombocytopenia occurred in 12 of 1333 patients treated with aminoglutethimide (0." | 3.67 | Aminoglutethimide-induced hematologic toxicity: worldwide experience. ( Boucher, AE; Buzdar, AU; Harvey, HA; Henderson, IC; Lipton, A; Messeih, AA; Murray, R; Nagel, GA; Ragaz, J; Santen, RJ, 1985) |
| "This study was performed to determine the toxicity and effectiveness of megestrol acetate used with aminoglutethimide-hydrocortisone in the treatment of patients with metastatic breast cancer." | 3.67 | Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. ( Gale, KE; Hahn, RG; Horton, J; Keller, AM; Knuiman, M; Rosenbluth, RJ; Tormey, DC; Vogel, H, 1987) |
| "45 women (postmenopausal or after former oophorectomy) with metastatic breast cancer resistant to tamoxifen as well as to chemo- and radiotherapy were treated with aminoglutethimide (750 mg or 1000 mg resp." | 3.67 | [Aminoglutethimide therapy in advanced breast cancer]. ( Kühböck, J; Ludwig, H; Pötzi, P; Zielinski, C, 1985) |
| "Two hundred and thirteen unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone." | 3.66 | Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Harmer, CL; Harris, AL; McKinna, JA; Morgan, M; Parsons, CA; Powles, TJ; Smith, IE; White, H, 1983) |
| "We describe sequential response to aminoglutethimide after eventual failure of treatment with tamoxifen in a patient with metastatic breast cancer." | 3.66 | Response to aminoglutethimide after tamoxifen therapy in advanced breast cancer. ( Allison, RW; Furnival, CM; Lee, JF; Roberts, SJ, 1982) |
| "In 114 patients with metastatic breast cancer resistant to chemo- and hormonal therapy another attempt was made to treat these patients with the hormone combination of aminoglutethimide (AG) 1000 mg daily and medroxyprogesteroneacetate (MAP) 1500 mg daily for 6 weeks, than 500 mg MAP daily." | 3.66 | [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force]. ( Blossey, HC; Nagel, GA; Wander, HE, 1982) |
| "Thirty-eight metastatic breast cancer patients were treated with aminoglutethimide." | 3.66 | Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. ( Blumenschein, GR; Buzdar, AU; Legha, SS; Powell, KC, 1982) |
| "Sixty-five patients with actively progressing advanced breast cancer were treated with aminoglutethimide, a drug which inhibits adrenal steroid synthesis and decreases peripheral conversion of androgens to oestrogens." | 3.66 | Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer. ( Jerums, G; Murray, RM; Pitt, P, 1981) |
| "Seventy-three women with metastatic breast cancer were treated with aminoglutethimide and dexamethasone." | 3.66 | Treatment of metastatic breast cancer with aminoglutethimide. ( Asbury, RF; Bakemeier, RF; Bennett, JM; Fölsch, E; McCune, CS; Savlov, E, 1981) |
| "Aminoglutethimide was applied for treatment of 10 patients (8 postmenopausal, 2 ovariectomized) with metastasizing breast cancer." | 3.66 | [Treatment of metastasizing breast cancer with aminoglutethimide]. ( Aiginger, P; Kübböck, J; Linkesch, W; Ludwig, H; Pötzi, P, 1982) |
| "Medical adrenalectomy, consisting of aminoglutethimide plus either dexamethasone or hydrocortisone, was administered to 53 women with advanced breast cancer." | 3.66 | Medical adrenalectomy in patients with advanced breast cancer. ( Brown, PW; Horsley, JS; Lawrence, W; Neifeld, JP; Newsome, HH; Terz, JJ, 1982) |
| "In conclusion, in a group of metastatic breast cancer patients, treated routinely by systemic therapies it was found, that the use of higher cut-off point for EGF-R positivity can improve the prediction of endocrine sensitivity." | 2.69 | Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction. ( Branković-Magić, MV; Mitrovic, LB; Nesković-Konstantinović, ZB; Nikolić-Vukosavljević, DB; Spuzić, I, 2000) |
| "Aminoglutethimide (Elipten), at a dosage between 250 and 1500 mg/d by mouth, was administered in a clinical phase II study to 17 patients with metastasizing carcinoma of the breast resistant to hormones and cytostatic drugs." | 2.65 | [Aminoglutethimide in metastasizing carcinoma of the breast resistant to hormonal and cytostatic treatment (author's transl)]. ( Rieche, K, 1981) |
| "Almost all patients with prostatic cancer will eventually escape the control of the first-line endocrine therapy and relapse." | 2.38 | Management of relapsing disease in prostate cancer. ( Denis, L; Mahler, C, 1992) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 2.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "Twenty-nine patients with metastatic prostate cancer were treated with simultaneous flutamide withdrawal and aminoglutethimide (250 mg given orally four times daily)." | 1.29 | Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. ( Cooper, M; Figg, WD; Headlee, D; Linehan, WM; Myers, CE; Sartor, O; Steinberg, S; Thibault, A; Tompkins, A; Weinberger, M, 1994) |
| "Of 221 patients with breast cancer of known epidermal growth factor receptor (EGFR) and oestrogen receptor (ER) status, 99 had developed recurrences during the period of follow-up (range 3-60 months, median 24 months)." | 1.28 | Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. ( Angus, B; Cairns, J; Farndon, J; Harris, AL; Horne, CH; Nicholson, S; Sainsbury, JR; Wright, C, 1992) |
| "As breast cancer is responsive to hormonal therapy, AG has been used in the treatment of metastatic breast cancer." | 1.28 | [The use of aminoglutethimide in the treatment of metastatic breast cancer]. ( Bellora, MG; Bergamino, T; Ciancio, A; Ferrero, A; Sismondi, P; Zola, P, 1991) |
| "In 57 patients with metastasized breast carcinoma, serum CEA levels (CEA-Ria-Kit, Abbot) were correlated with the clinical course under endocrine or cytostatic therapy." | 1.27 | [Prognostic value of serum CEA and therapy-induced nonspecific CEA levels in metastasizing breast carcinoma]. ( Garbrecht, M; Kleeberg, UR; Müllerleile, U; Pompecki, R; Treidler, J, 1984) |
| "A total of 79 patients with metastatic breast cancer entered the study, and their plasma and urine samples were analyzed by high-performance liquid chromatography (HPLC)." | 1.27 | Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ( Höffken, K; Miller, AA; Miller, BE; Schmidt, CG, 1987) |
| "Hormone-dependent breast carcinomas respond to deprivation of biologically active estrogens with objectively quantifiable tumor regression." | 1.26 | Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. ( Boucher, A; Harvey, H; Lipton, A; Samojlik, E; Santen, RJ; Wells, SA; Worgul, TJ, 1982) |
| "Aminoglutethimide is an investigational agent of proven benefit in the treatment of metastatic breast carcinoma." | 1.26 | Pancytopenia induced by aminoglutethimide in the treatment of breast cancer. ( Hamilton, R; Harvey, HA; Lawrence, B; Lipton, A; Mercurio, T; Santen, RJ, 1978) |
| "42 patients with metastatic breast carcinoma were treated with aminoglutethimide, which inhibits adrenal steroid hormone synthesis." | 1.26 | Aminoglutethimide in treatment of metastatic breast carcinoma. ( Fahmy, DR; Fitzharris, BM; Ford, HT; Gazet, JC; McKinna, JA; Nash, AG; Neville, AM; Powles, TJ; Smith, IE, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 83 (79.81) | 18.7374 |
| 1990's | 16 (15.38) | 18.2507 |
| 2000's | 4 (3.85) | 29.6817 |
| 2010's | 1 (0.96) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kadhirvel, P | 1 |
| Azenha, M | 1 |
| Schillinger, E | 1 |
| Halhalli, MR | 1 |
| Silva, AF | 1 |
| Sellergren, B | 1 |
| Rose, C | 4 |
| Kruit, WH | 1 |
| Stoter, G | 1 |
| Klijn, JG | 1 |
| Buzdar, AU | 2 |
| Powell, KC | 1 |
| Legha, SS | 1 |
| Blumenschein, GR | 1 |
| Wander, HE | 5 |
| Nagel, GA | 6 |
| Blossey, HC | 4 |
| Stuart-Harris, RC | 1 |
| Smith, IE | 3 |
| Treidler, J | 1 |
| Pompecki, R | 1 |
| Müllerleile, U | 1 |
| Garbrecht, M | 1 |
| Kleeberg, UR | 2 |
| Santen, RJ | 15 |
| Wells, SA | 9 |
| Allison, RW | 1 |
| Furnival, CM | 1 |
| Lee, JF | 1 |
| Roberts, SJ | 1 |
| Mouridsen, HT | 3 |
| Palshof, T | 1 |
| Mattheiem, W | 1 |
| Sylvester, RJ | 1 |
| Rotmensz, N | 1 |
| Paridaens, RJ | 1 |
| Murray, RM | 1 |
| Pitt, P | 2 |
| Jerums, G | 1 |
| Brufman, G | 3 |
| Biran, S | 3 |
| Harris, AL | 2 |
| Powles, TJ | 4 |
| Coombes, RC | 3 |
| Ford, HT | 2 |
| Gazet, JC | 2 |
| Harmer, CL | 1 |
| Morgan, M | 1 |
| White, H | 1 |
| Parsons, CA | 1 |
| McKinna, JA | 2 |
| Lipton, A | 12 |
| Harvey, HA | 5 |
| Boucher, A | 2 |
| White, D | 2 |
| Bernath, A | 1 |
| Dixon, R | 1 |
| Richards, G | 1 |
| Shafik, A | 1 |
| Szepesi, T | 1 |
| Schratter-Sehn, AU | 1 |
| Williams, C | 1 |
| Buchanan, R | 1 |
| Worgul, TJ | 3 |
| Samojlik, E | 6 |
| Interrante, A | 1 |
| Boucher, AE | 3 |
| White, DS | 2 |
| Smart, E | 3 |
| Cox, C | 2 |
| Harvey, H | 5 |
| Gordon, C | 1 |
| Horsley, JS | 1 |
| Newsome, HH | 1 |
| Brown, PW | 2 |
| Neifeld, JP | 1 |
| Terz, JJ | 2 |
| Lawrence, W | 1 |
| Sterns, EE | 1 |
| Bird, CE | 1 |
| Mackie, KW | 1 |
| Kübböck, J | 1 |
| Ludwig, H | 2 |
| Aiginger, P | 1 |
| Linkesch, W | 1 |
| Pötzi, P | 2 |
| Asbury, RF | 1 |
| Bakemeier, RF | 1 |
| Fölsch, E | 1 |
| McCune, CS | 1 |
| Savlov, E | 1 |
| Bennett, JM | 2 |
| Rieche, K | 1 |
| Paridaens, R | 1 |
| Van Haelen, C | 1 |
| Heuson, JC | 1 |
| Henderson, IC | 2 |
| Canellos, GP | 1 |
| Sartor, O | 1 |
| Cooper, M | 1 |
| Weinberger, M | 1 |
| Headlee, D | 1 |
| Thibault, A | 1 |
| Tompkins, A | 1 |
| Steinberg, S | 1 |
| Figg, WD | 1 |
| Linehan, WM | 1 |
| Myers, CE | 1 |
| Freeman, DA | 1 |
| Garcia-Giralt, E | 1 |
| Omodei Zorini, C | 1 |
| Ferri, L | 1 |
| Ayme, Y | 1 |
| Carton, M | 1 |
| Daban, A | 1 |
| Delozier, T | 1 |
| Fargeot, P | 2 |
| Fumoleau, P | 1 |
| Gorins, A | 1 |
| Pronzato, P | 3 |
| Rubagotti, A | 1 |
| Amoroso, D | 1 |
| Bertelli, G | 2 |
| Queirolo, P | 1 |
| Sertoli, MR | 1 |
| Rosso, M | 2 |
| Gallotti, P | 1 |
| Monzeglio, C | 1 |
| Rosso, R | 2 |
| Hultborn, R | 1 |
| Johansson-Terje, I | 1 |
| Bergh, J | 1 |
| Glas, U | 1 |
| Hallsten, L | 1 |
| Hatschek, T | 1 |
| Holmberg, E | 1 |
| Ideström, K | 1 |
| Norberg, B | 1 |
| Ranstam, J | 1 |
| Söderberg, M | 1 |
| Wallgren, UB | 1 |
| Bare, RL | 1 |
| Torti, FM | 1 |
| Kamby, C | 3 |
| Andersson, M | 1 |
| Bastholt, L | 2 |
| Møller, KA | 1 |
| Andersen, J | 1 |
| Munkholm, P | 1 |
| Dombernowsky, P | 2 |
| Christensen, IJ | 1 |
| Nesković-Konstantinović, ZB | 1 |
| Nikolić-Vukosavljević, DB | 1 |
| Branković-Magić, MV | 1 |
| Mitrovic, LB | 1 |
| Spuzić, I | 1 |
| Fitzharris, BM | 1 |
| Fahmy, DR | 1 |
| Nash, AG | 1 |
| Neville, AM | 1 |
| Veldhuis, J | 1 |
| Ruby, EB | 1 |
| Kendall, J | 1 |
| Lawrence, B | 1 |
| Hamilton, R | 1 |
| Mercurio, T | 1 |
| Osterman, J | 1 |
| McElduff, A | 1 |
| Clifton-Bligh, P | 1 |
| Posen, S | 1 |
| Haagensen, DE | 2 |
| Ruby, EJ | 1 |
| Dilley, WG | 1 |
| Koelmeyer, TD | 1 |
| Stephens, EJ | 1 |
| Wood, HF | 1 |
| Misbin, RJ | 1 |
| Misbin, R | 1 |
| Wright, C | 1 |
| Nicholson, S | 1 |
| Angus, B | 1 |
| Sainsbury, JR | 1 |
| Farndon, J | 1 |
| Cairns, J | 1 |
| Horne, CH | 1 |
| Mahler, C | 1 |
| Denis, L | 1 |
| Schmidt, UM | 2 |
| Brockmann, B | 1 |
| Geschke, E | 1 |
| Bellora, MG | 1 |
| Ciancio, A | 1 |
| Ferrero, A | 1 |
| Bergamino, T | 1 |
| Zola, P | 1 |
| Sismondi, P | 1 |
| Namer, M | 1 |
| Voznyĭ, EK | 1 |
| Meshcheriakova, NG | 1 |
| Biakhov, MIu | 1 |
| Vasiuta, NIu | 1 |
| Hardy, JR | 1 |
| Judson, IR | 1 |
| Sinnett, HD | 1 |
| Ashley, SE | 1 |
| Ellin, CL | 1 |
| Stier, G | 1 |
| Gürtler, R | 1 |
| Müller, U | 1 |
| Tanneberger, S | 1 |
| Chang, AY | 1 |
| Pandya, KJ | 1 |
| Asbury, R | 1 |
| McCune, C | 1 |
| Lundgren, S | 1 |
| Gundersen, S | 1 |
| Klepp, R | 1 |
| Lønning, PE | 1 |
| Lund, E | 1 |
| Kvinnsland, S | 1 |
| Geller, J | 1 |
| Albert, JD | 1 |
| Samonigg, H | 1 |
| Kleeberg, U | 1 |
| Manni, A | 1 |
| Essers, U | 1 |
| Van Deijk, WA | 1 |
| Blijham, GH | 1 |
| Mellink, WA | 1 |
| Meulenberg, PM | 1 |
| Teichmann, AT | 1 |
| Cremer, P | 1 |
| Wieland, H | 1 |
| Kruse, B | 1 |
| Kuhn, W | 1 |
| Seidel, D | 1 |
| Grem, JL | 1 |
| Falkson, G | 1 |
| Love, RR | 1 |
| Tormey, DC | 2 |
| Bonneterre, J | 2 |
| Pion, JM | 1 |
| Demaille, A | 1 |
| Horton, J | 1 |
| Knuiman, M | 1 |
| Keller, AM | 1 |
| Vogel, H | 1 |
| Gale, KE | 1 |
| Hahn, RG | 1 |
| Rosenbluth, RJ | 1 |
| Ingle, JN | 1 |
| Green, SJ | 1 |
| Ahmann, DL | 1 |
| Long, HJ | 1 |
| Edmonson, JH | 1 |
| Rubin, J | 1 |
| Chang, MN | 1 |
| Creagan, ET | 1 |
| Brincker, H | 1 |
| Skovgaard-Poulsen, H | 1 |
| Andersen, AP | 1 |
| Loft, H | 1 |
| Andersen, KW | 1 |
| Nadezhdina, TM | 1 |
| Vyshinskaia, GV | 1 |
| Lichinitser, MR | 1 |
| Bassalyk, LS | 1 |
| Garin, AM | 1 |
| Rowell, NP | 1 |
| Gilmore, OJ | 1 |
| Plowman, PN | 1 |
| Gorgone, S | 1 |
| Lorenzini, C | 1 |
| Palmeri, R | 1 |
| Belnome, N | 1 |
| Calbo, L | 1 |
| Dattola, P | 1 |
| Melita, P | 1 |
| Crawford, ED | 1 |
| Ahmann, FR | 1 |
| Davis, MA | 1 |
| Levasseur, YJ | 1 |
| Nemoto, T | 1 |
| Miller, AA | 3 |
| Miller, BE | 1 |
| Höffken, K | 3 |
| Schmidt, CG | 3 |
| Miller, B | 2 |
| Becher, R | 2 |
| Aulbert, E | 1 |
| Hoffmann, B | 1 |
| Anders, CU | 1 |
| Callies, R | 1 |
| Paterson, AH | 1 |
| Ardizzoni, A | 1 |
| Lionetto, R | 1 |
| Conte, P | 1 |
| Coppens, H | 1 |
| Mauriac, L | 1 |
| Metz, M | 1 |
| Rouesse, J | 1 |
| Armand, JP | 1 |
| Mathieu, M | 1 |
| Tubiana, M | 1 |
| Cappelaere, P | 1 |
| Dubost, JJ | 1 |
| Sauvezie, B | 1 |
| Ristori, JM | 1 |
| Thevenet, JP | 1 |
| Rampon, S | 1 |
| Murray, R | 2 |
| Messeih, AA | 1 |
| Ragaz, J | 1 |
| Blankenstein, MA | 1 |
| Bakker, GH | 1 |
| Kühböck, J | 1 |
| Zielinski, C | 1 |
| Carey, RM | 1 |
| Orth, DN | 1 |
| Hartmann, WH | 1 |
| Cash, R | 2 |
| Brough, AJ | 1 |
| Cohen, MN | 1 |
| Satoh, PS | 1 |
| Schein, PS | 1 |
| Corrin, B | 1 |
| Gilby, ED | 1 |
| Jones, NF | 1 |
| Patrick, J | 1 |
| Belchetz, PE | 1 |
| Brown, CL | 1 |
| Makin, HL | 1 |
| Trafford, DJ | 1 |
| Mason, AS | 1 |
| Bloom, SR | 1 |
| Ratcliffe, JG | 1 |
| Robinson, MR | 2 |
| Shearer, RJ | 1 |
| Fergusson, JD | 1 |
| Griffiths, CT | 1 |
| Hall, TC | 1 |
| Saba, Z | 1 |
| Barlow, JJ | 1 |
| Nevinny, HB | 1 |
| Givens, JR | 1 |
| Camacho, A | 1 |
| Patterson, P | 1 |
| Thomas, BS | 1 |
| Miranda-Zetterstrand, N | 1 |
| Díaz-Bonet, L | 1 |
| Pagán-Sáez, H | 1 |
| Rosaly de Jirau, W | 1 |
| Schteingart, DE | 1 |
| Conn, JW | 1 |
12 reviews available for aminoglutethimide and Neoplasm Metastasis
| Article | Year |
|---|---|
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2003 |
Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic C | 2004 |
Aminoglutethimide in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; | 1984 |
[Hormones and tumor therapy: current clinical status and future developments in endocrine therapy of breast cancer].
Topics: Adrenal Cortex Hormones; Adrenalectomy; Aminoglutethimide; Androgens; Breast Neoplasms; Castration; | 1982 |
Endocrine therapy of prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Antineoplasti | 1998 |
Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Topics: Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehy | 1977 |
Management of relapsing disease in prostate cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Estrogens | 1992 |
Adrenal androgen blockade in relapsed prostate cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Castration; Combined Modality Therapy; Cypro | 1985 |
Tamoxifen therapy of metastatic breast cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clin | 1987 |
[New hormonal treatments of metastatic prostatic cancer. Review of the literature].
Topics: Aminoglutethimide; Androgen Antagonists; Animals; Antineoplastic Agents; Combined Modality Therapy; | 1985 |
[Hormone therapy of metastatic breast carcinoma].
Topics: Aminoglutethimide; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Buserelin; Female; | 1985 |
Chemotherapeutic management of the hormone-secreting endocrine malignancies.
Topics: Adenoma, Islet Cell; Adrenal Gland Neoplasms; Aminoglutethimide; Aniline Compounds; Antibiotics, Ant | 1972 |
28 trials available for aminoglutethimide and Neoplasm Metastasis
| Article | Year |
|---|---|
Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic C | 2004 |
Aminoglutethimide in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; | 1984 |
Ablative procedures in patients with metastatic breast carcinoma.
Topics: Adrenal Cortex; Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Clinica | 1984 |
Currently active protocols in the EORTC Breast Cancer Cooperative Group.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1984 |
A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Castration; Clinical Trials as Topic; Female; Humans; Menopause | 1982 |
A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Hormones; Huma | 1981 |
Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Hydroc | 1982 |
Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone.
Topics: Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Danazol; Drug Therapy, Combination; F | 1982 |
[Aminoglutethimide in metastasizing carcinoma of the breast resistant to hormonal and cytostatic treatment (author's transl)].
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Middle Aged; Nause | 1981 |
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Drug Resistance; Female; Humans | 1994 |
Second-line hormonotherapy for breast cancer. Uselessness of first-line continuation.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; H | 1993 |
A randomized trial on tamoxifen continuation during second-line hormone therapy in breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Middle Aged; Neoplasm Metastasi | 1993 |
Second-line endocrine treatment of advanced breast cancer--a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Humans; Me | 1996 |
Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined | 2000 |
Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2000 |
A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Cerebrospinal Fluid Rhinorrhea; Clinical Trials as | 1979 |
Second line hormonal therapy with aminoglutethimide in metastatic breast cancer.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Estrogen An | 1990 |
Megestrol acetate versus aminoglutethimide for metastatic breast cancer.
Topics: Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Megest | 1989 |
Tamoxifen therapy of metastatic breast cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clin | 1987 |
[Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Combined Modal | 1987 |
[Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast].
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; D | 1987 |
Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cl | 1986 |
Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop | 1986 |
Metastatic pattern and response to endocrine therapy in human breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Diethylstilbestrol; Female; Fluoxymesterone; Humans; Medroxypro | 1986 |
Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer.
Topics: Age Factors; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle A | 1985 |
Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; F | 1985 |
Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aminoglutethimide; Anim | 1967 |
Effect of aminoglutethimide and reserpine on the human pituitary-adrenal axis: remission of a case of Cushing's disease.
Topics: 17-Hydroxycorticosteroids; Addison Disease; Adrenal Glands; Adult; Aldosterone; Aminoglutethimide; A | 1970 |
67 other studies available for aminoglutethimide and Neoplasm Metastasis
| Article | Year |
|---|---|
Recognitive nano-thin-film composite beads for the enantiomeric resolution of the metastatic breast cancer drug aminoglutethimide.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, High Pressure | 2014 |
Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Dizziness; Edema; Female; Fever; Humans; Middle Ag | 1982 |
[Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Delayed-Action Preparations | 1982 |
[Prognostic value of serum CEA and therapy-induced nonspecific CEA levels in metastasizing breast carcinoma].
Topics: Adult; Aged; Alkaline Phosphatase; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Combined | 1984 |
The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Aminoglutethimide; Antineoplastic Agents; Breast Neopla | 1980 |
Response to aminoglutethimide after tamoxifen therapy in advanced breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Drug Administration Sc | 1982 |
Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer.
Topics: Adrenal Glands; Aminoglutethimide; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone | 1981 |
[Treatment of metastatic breast cancer with aminoglutethimide after failure of tamoxifen].
Topics: Aminoglutethimide; Breast Neoplasms; Humans; Neoplasm Metastasis; Tamoxifen | 1984 |
Aminoglutethimide as an aromatase inhibitor in the treatment of cancer.
Topics: Aminoglutethimide; Androgens; Animals; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Hu | 1984 |
Aminoglutethimide for the treatment of advanced postmenopausal breast cancer.
Topics: Adult; Age Factors; Aged; Aminoglutethimide; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combin | 1983 |
Choosing treatment for metastatic breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Hormones; Humans; Middle Aged; Neoplasm Metastasi | 1982 |
Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma.
Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Estrogens; Female; Glucocorticoids; Humans; Menopaus | 1982 |
Medical adrenalectomy in patients with advanced breast cancer.
Topics: Adrenal Glands; Adrenalectomy; Adult; Aminoglutethimide; Breast Neoplasms; Dexamethasone; Female; Fl | 1982 |
Is aminoglutethimide an alternative to adrenalectomy for metastatic carcinoma of the breast?
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Female; | 1982 |
[Treatment of metastasizing breast cancer with aminoglutethimide].
Topics: Aged; Aminoglutethimide; Ataxia; Breast Neoplasms; Carcinoembryonic Antigen; Drug Resistance; Estrad | 1982 |
Treatment of metastatic breast cancer with aminoglutethimide.
Topics: Aminoglutethimide; Breast Neoplasms; Dexamethasone; Female; Hormones; Humans; Middle Aged; Nausea; N | 1981 |
Medical adrenalectomy with aminoglutethimide-cortisol in the treatment of metastatic breast carcinoma.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Hydrocortisone | 1980 |
Cancer of the breast: the past decade (second of two parts).
Topics: Adrenalectomy; Adult; Age Factors; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Castr | 1980 |
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Flutamid | 1994 |
Adrenal carcinoma.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Aminoglutethimide; Carcinoma; Cushing Syndrome; Dia | 1994 |
Aminoglutethimide in treatment of metastatic breast carcinoma.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neopl | 1978 |
Mechanism of action of aminoglutethimide in breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Estradiol; Estrogen Antagonists; | 1979 |
Pancytopenia induced by aminoglutethimide in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; | 1978 |
Breast carcinoma associated with Klinefelter syndrome: a case report.
Topics: Adrenal Glands; Adult; Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; | 1978 |
Metastatic medullary carcinoma of the thyroid complicated by Cushing's syndrome.
Topics: Adult; Aminoglutethimide; Carcinoma; Cushing Syndrome; Dexamethasone; Drug Therapy, Combination; Hum | 1979 |
Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma.
Topics: Adrenal Cortex; Adrenalectomy; Aldosterone; Aminoglutethimide; Androstenedione; Bone Neoplasms; Brea | 1978 |
Experience with 6-aminoglutethimide in the treatment of metastatic breast cancer.
Topics: Adrenal Glands; Aminoglutethimide; Betamethasone; Breast Neoplasms; Drug Therapy, Combination; Femal | 1978 |
Aminoglutethimide for metastatic breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Neoplasm Metastasis | 1977 |
Studies in patients with metastatic breast carcinoma treated with aminoglutethimide for medical adrenalectomy.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Dexamethasone; Drug Therapy, Combination; Female | 1976 |
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Biomarkers, Tumor; Breast Neoplasms; ErbB Receptors; Female; Follow- | 1992 |
[Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Female; Follow-Up Studies; Huma | 1991 |
[The use of aminoglutethimide in the treatment of metastatic breast cancer].
Topics: Adrenal Glands; Age Factors; Aminoglutethimide; Androstenedione; Breast Neoplasms; Female; Humans; M | 1991 |
[Reflexions on hormone therapy of cancer of the breast].
Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Estrogens; Female; Humans; Medroxyprogesterone Aceta | 1991 |
[Hormonal control of disseminated breast cancer].
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Delayed-Action Preparations; Estrogen An | 1990 |
Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast N | 1990 |
[Experiences with Rodazol therapy in the treatment of postmenopausal patients with metastatic breast cancer].
Topics: Administration, Oral; Aminoglutethimide; Breast Neoplasms; Drug Administration Schedule; Female; Fol | 1990 |
[Palliative treatment of skeletal metastases in patients with breast carcinoma].
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Megestrol; Neoplasm Metastasis; Palliative Care | 1987 |
A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma.
Topics: Aminoglutethimide; Carcinoma; Drug Evaluation; Drug Therapy, Combination; Humans; Hydrocortisone; Ma | 1989 |
[Value of hormone therapy in metastasizing breast cancer].
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Medroxyprogesterone; Med | 1985 |
Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO).
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brea | 1986 |
Treatment of metastatic breast cancer with aminoglutethimide after progression on chemotherapy and/or hormonal therapy with tamoxifen.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; | 1985 |
Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Topics: Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Medr | 1985 |
[Changes in serum lipoproteins under hormonal therapy of breast carcinoma and other endocrine-dependent tumors].
Topics: Aminoglutethimide; Breast Neoplasms; Cholesterol; Cortisone; Drug Therapy, Combination; Female; Huma | 1985 |
A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 1988 |
Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; B | 1987 |
[The use of aminoglutethimide (orimeten) in disseminated breast cancer].
Topics: Adult; Aminoglutethimide; Breast Neoplasms; Female; Follow-Up Studies; Humans; Menopause; Middle Age | 1987 |
Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Middle Aged; Neopl | 1987 |
[Aminoglutethimide in the treatment of metastasizing breast carcinoma in old age].
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged | 1987 |
Aminoglutethimide in metastatic adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Aminoglutethimide; Humans; Hydrocortisone; Male; Mid | 1987 |
Endocrine therapy of metastatic breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Neoplasm Metastasis; Ovariectomy; Progesterone | 1987 |
Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Chromatography, High Pressure Liquid; Female; Foll | 1987 |
[Low-dose aminoglutethimide therapy without cortisol substitution in postmenopause metastasizing breast cancer].
Topics: Aminoglutethimide; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation; Female; Huma | 1986 |
Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer.
Topics: Adult; Aminoglutethimide; Breast Neoplasms; Cortisone; Female; Humans; Menopause; Middle Aged; Neopl | 1986 |
Chemotherapy and hormone therapy of metastatic breast cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali | 1985 |
Treatment of advanced prostatic cancer, resistant to conventional therapy, with aminoglutethimide.
Topics: Aged; Aminoglutethimide; Castration; Combined Modality Therapy; Estrogens; Follow-Up Studies; Humans | 1985 |
Aminoglutethimide-induced hematologic toxicity: worldwide experience.
Topics: Aminoglutethimide; Blood Cell Count; Breast Neoplasms; Female; Global Health; Hematologic Diseases; | 1985 |
Rationale for suppression of adrenal steroidogenesis in advanced prostatic cancer.
Topics: Adrenal Cortex Hormones; Aminoglutethimide; Androgen Antagonists; Androgens; Animals; Estrogens; Hum | 1985 |
[Aminoglutethimide therapy in advanced breast cancer].
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Middle | 1985 |
Malignant melanoma with ectopic production of adrenocorticotropic hormone. Palliative treatment with inhibitors of adrenal steroid biosynthesis.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenocortical Hyperfunction; Adrenocorticotropic Hormon | 1973 |
Oat cell carcinoma of the pancreas with ectopic ACTH secretion.
Topics: Adrenocorticotropic Hormone; Aminoglutethimide; Autopsy; Biopsy; Carcinoma, Bronchogenic; Carcinoma, | 1973 |
ACTH, glucagon and gastrin production by a pancreatic islet cell carcinoma and its treatment.
Topics: Adenoma, Islet Cell; Adrenocorticotropic Hormone; Adult; Aminoglutethimide; Gastrins; Glucagon; Horm | 1973 |
Adrenal suppression in the treatment of carcinoma of the prostate.
Topics: Acid Phosphatase; Administration, Oral; Adrenal Glands; Aged; Alkaline Phosphatase; Aminoglutethimid | 1974 |
Preliminary trial of aminoglutethimide in breast cancer.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Administration, Oral; Aminoglutethimide; Antineoplastic | 1973 |
Proceedings: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer.
Topics: Adrenal Glands; Adrenalectomy; Adult; Aged; Aminoglutethimide; Binding, Competitive; Breast Neoplasm | 1974 |
Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma.
Topics: Age Factors; Aged; Aminoglutethimide; Castration; Diethylstilbestrol; Estrogens; Humans; Male; Middl | 1971 |
Amino-glutethimide (elipten) in adenocortical carcinoma.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenal Gland Neoplasms; Adrenocortical Hyperfunction; A | 1968 |
Amino-glutethimide and metastatic adrenal cancer. Maintained reversal (six months) of Cushing's syndrome.
Topics: Adrenal Gland Neoplasms; Adult; Aminoglutethimide; Anticonvulsants; Antineoplastic Agents; Carbon Is | 1966 |